Pagina 12 - I migliori medici di Risonanza magnetica di un'area - TOP-519medici

Membership in societies:

Expert of scientific journals 

Close co-operation with leading surgeons

Membership of the German Medical Association 

Specialities:

Introduction of new and modern techniques in the field of oncological surgery
General and visceral surgery

Minimally invasive surgery

Gastrointestinal oncology surgery

Oncological surgery

Haemorrhoids treatment

Additional clinical specialisation in minimally invasive and hernia surgery

Surgery and transplantation of the pancreas

Work Experience:

2005: Specialist in the field of surgery

2008: Appointed Senior Consultant specialising in pancreatic surgery and transplantation

2010: Coordinator of the Pancreatic Cancer Centre (Oncocert)

2013: Specialist in visceral surgery

2014: Managing Senior Physician, additional clinical specialisation in minimally invasive and hernia surgery

2019: Chief Surgeon of the Colorectal Cancer Centre Bochum (the first certified colorectal cancer centre in Germany and one of the first certified leading colorectal centres in Europe)

2021: Chief Surgeon of the Department of Surgery at the Academic Hospital Solingen

Thanks to the professor and his team, the department has been modernised by introducing modern surgical methods of treatment and especially improved methods of post-operative recovery. The Department of Surgery at the Solingen Clinic is now further expanding its focus on minimally invasive surgery in the direction of robotics. The clinic has allocated a huge budget for the purchase of state-of-the-art equipment in order to offer patients a full range of surgical methods for the treatment of benign and malignant diseases of the oesophagus, lungs, stomach, liver, pancreas and intestines according to current guidelines and using the most modern technical equipment.

Professor Schenker is an active researcher and lecturer. He lectures at medical universities and organises seminars and workshops for colleagues. He cooperates closely with the Cancer Centre, the Pancreatic Cancer Treatment Centre, the Intestinal Cancer Treatment Centre and the Interregional Trauma Centre.

Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology

Education:

• 2004-2011: İnönü University Faculty of Medicine
• 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
• 2017-2022: Health Sciences University, Medical Oncology

Professional Experience:

• 2016-2017: Bingöl City Hospital, Internal Medicine
• 2021-2022: Health Sciences University, Medical Oncology
• 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
• 2023-2024: Ohio State University, Medical Oncology
• 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

Clinical Trials, Courses, Certifications:

Clinical Trials:

• 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
• 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

Courses:

• 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
• 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
• 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
• 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
• 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

Certifications:

• Ongoing: ECFMG Certification
• 2024: CITI Responsible Conduct of Research (The Ohio State University)
• 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
• 2024: CITI Human Subjects Protection (The Ohio State University)
• 2024: CITI Good Clinical Practice (The Ohio State University)
• 2023: Occupational English Test (OET)
• 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
• 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
• 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

Memberships:

• American Society of Clinical Oncology (ASCO) - 2022
• Turkish Society of Medical Oncology - 2020

Pichai Kittipanyaworakul, M.D.
Pichai Kittipanyaworakul, M.D.

INTERNAL MEDICINE / GASTROENTEROLOGIST AND HEPATOLOGIST

Graduation (M.D. From)

Bachelor of Medicine, Faculty of Medicine, Chiang Mai University

Certificates

Diploma in Internal Medicine, Faculty of Medicine, Chulalongkorn Memorial Hospital, Thai Red Cross Society

Diploma of Internal Medicine in Gastroenterology and Hepatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University

Current Positions

INTERNAL MEDICINE / GASTROENTEROLOGIST AND HEPATOLOGIST AT INTRARAT HOSPITAL

Education & Academic Qualifications

License (MD)

Field: Medicine

University: Istanbul University

Year: 1987

Residency

Field: Cardiovascular Surgery

Institution: Siyami Ersek Heart Center

Years: 1988–1994

Clinical Fellowship

Field: Cardiovascular Surgery

Institution: University of Ottawa Heart Center (Canada)

Years: 1994–1995

Academic Titles & Positions

Assistant Professor

Field: Cardiovascular Surgery

Institution: Siyami Ersek Heart Center

Years: 1995–2008

Professor

Field: Cardiovascular Surgery

Institution: Altınbaş University

Years: 2014–2019

Membership in Scientific and Professional Organizations

-Turkish Society of Cardiovascular Surgery

-European Society for Cardiovascular Surgery

-European Society for Vascular Surgery

Education & Expertise

• 1997 | Hacettepe University Faculty of Medicine – Medical Degree
• 2003 | Uludağ University Faculty of Medicine – Internal Medicine Specialization
• 2007 | Uludağ University Faculty of Medicine – Hematology Subspecialty

Professional Experience

• 1998 (May – September) | Practitioner, Dr. Salaha Health Center, Rize
• 1998 to 2003 | Research Assistant, Uludağ University Faculty of Medicine, Internal Medicine Department
• 2003 to 2007 | Hematology Subspecialist, Uludağ University Faculty of Medicine, Hematology Division
• 2007 to 2011 | Hematology Specialist, Bursa Ali Osman Sönmez Oncology Hospital (Compulsory Service)
• 2011 to 2013 | Hematology Specialist, Private Anadolu Health Center Bone Marrow Transplant Center, Gebze
• 2014 to 2015 | Assistant Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine
• 2015 to 2020 | Associate Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine
• 2020 to Present | Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine

Courses & Certifications

• Autologous and Allogeneic Stem Cell Transplantation Certificate
• Clinical Phytotherapy Application Certificate
• Flow Cytometry Experience Certificate
• EBMT Stem Cell Transplantation Course

Professional Memberships

• Turkish Medical Chamber
• Turkish Hematology Association (Full Member, No: 893)
• Turkish Therapeutic Apheresis Association (Current President)
• Geriatric Hematology Association
• Hematological Oncology Association
• EBMT (European Bone Marrow Transplantation)

Awards & Recognitions

• 2011 | 6th Turkish Therapeutic Apheresis Congress – Young Researcher Award

Prof. Emin Tireli, MD, is a leading pediatric cardiovascular surgeon. He has performed over 6,329 congenital cardiac surgeries since 1993. He is known worldwide for being one of the first to use the complex Nikaidoh procedure for transposition of the great arteries (TGA).

Dr. Tireli performs more than 100 neonatal cardiac surgeries each year. His expertise includes arterial switch operations, total pulmonary return anomalies, pulmonary banding, and Norwood procedures. He has used hybrid techniques in 15 cases. Dr. Tireli has also completed 30 reconstructions of aortic anomalies and many PDA ligations in extremely low birth weight infants. His work greatly supports neonatal care.

1997 - 2002 Università di Istanbul, Facoltà di Medicina, Cerrahpaşa, Dipartimento di Ortopedia e Traumatologia

1990 - 1996 Università di Istanbul, Facoltà di Medicina, Cerrahpaşa

Articoli che ha scritto e a cui ha partecipato;

Efficacia clinica delle iniezioni peritendinee di plasma ricco di piastrine nel trattamento delle tendinopatie: uno studio retrospettivo Aybars Kıvrak* (a), Mehmet Can Ünlü (a), Eşref Terzi (a), Olgar Birsel (b), Doruk Akgün (c), Yusuf Pirinççi (d), Gokhan Kaynak (a), Isık Akgün (e) Effetti a medio e lungo termine dell'anello acetabolare e delle cellule antiprotrusione Burch-Schneider nelle revisioni acetabolari in pazienti con deficit osseo acetabolare Corrispondenza: Yusuf Pirinççi, Muhammed Taha Demir, Mumammet Salih, Fahri Erdoğan, Necat Guney

I parametri dimensionali del femore prossimale nello sviluppo della displasia dell'anca adulta suggeriscono che una struttura conica, rettangolare a press-fit può essere la scelta ottimale per i pazienti con un'anca di tipo IV secondo Crowe.

Specialità

Chirurgia dello sport

Lacerazioni del menisco

Rotture del legamento crociato anteriore

Protesi di ginocchio

Protesi d'anca

Protesi di spalla

Riparazione del labbro glenoideo

Aumento dell'altezza

Chirurgia dei tumori

Chirurgia del piede (alluce valgo)

Piede diabetico

Infezioni ossee (osteomielite)

Prof. İbrahim Azboy, M.D.

Languages: English, Kurdish, Arabic

Orthopaedics and Traumatology
 

Areas of Expertise and Interest

• Hip & knee arthroplasty (primary, revision, robotic‑assisted)
• Infection prevention & management in joint replacements
• Minimally invasive and joint‑preserving orthopedic surgery
• Sports & trauma-related injuries (e.g. ACL, fractures)
• Osteoarthritis, cartilage damage & osteonecrosis

International Researcher IDs:  

• ORCID: 0000-0003-0926-3029 / Yoksis Researcher ID: 145243 

Education & Training

• 1994–2001: Hacettepe University, Faculty of Medicine
• 2002–2008: Ministry of Health Istanbul Training and Research Hospital
• 2014 & 2017: Hospital for Special Surgery, New York, USA – Knee and Hip Arthroplasty and Arthroscopy Training
• 2016: Rothman Institute, Thomas Jefferson University, Philadelphia, USA – Knee and Hip Arthroplasty and Hip Preserving Surgery Training

Academic & Professional Appointments

• 2021–Present: Professor, Istanbul Medipol University
• 2017–2020: Associate Professor, Istanbul Medipol University
• 2011–2017: Assistant Professor, Dicle University
• 2008–2011: Consultant MD, Şanlıurfa and Balıkesir Military Hospitals

Professional Memberships

• Member of 9 national and international orthopedic associations including:
  AAHKS, SICOT, EHS, KADAD, TOTBID, TOTEK, and TTB

Scientific & Educational Contributions

• Prof. Dr. İbrahim Azboy has authored over 70 internationally and 25 nationally peer-reviewed journal articles, contributed to 4 book chapters and 2 book translations, and presented at 25+ international and 65+ national congresses. He also serves as a reviewer for 13 scientific journals, including JBJS, JOA, SICOT-J, and JORR.

Teaching & Speaking Engagements

• Speaker/trainer in 20+ national courses and congresses on topics such as:
• Hip and knee arthroplasty
• Prosthetic joint infections
• VTE prophylaxis
• Surgical approaches and implant strategies

Dr. Hayrettin Kesmezacar is an orthopaedic surgeon at Gayrettepe Florence Nightingale Hospital in Istanbul. He joined the hospital in 2013 and holds a current appointment from 2024. His clinical focus includes shoulder and elbow surgery, shoulder instability, rotator cuff tears, and orthopaedic trauma.

He became Professor at Bilim University Medical Faculty in 2011. He was appointed Associate Professor at Istanbul University-Cerrahpaşa in 2006. His training includes residency and fellowship at Cerrahpaşa in 1997 and 2000. He completed visiting fellowships at Cornell HSS in 2004 and Western Ontario/LHSC in 2009. He holds a CRA certificate from Oxford College (2024). As of 2024, he serves as a CRA at Mount Sinai Hospital ICU Research (iCORE).

He has peer-reviewed publications in J Shoulder Elbow Surg, Acta Orthop Traumatol Turc, Arthroscopy, and others. His work includes a 22.4-year follow-up study on displaced supracondylar humerus fractures. He also reported 6-year outcomes for hallux valgus.

Dr. Mustafa Yavuz Samanci is an Associate Professor of Neurosurgery at Medipol Acıbadem District Hospital in Istanbul. He has specialized training in stereotactic, functional, and pediatric neurosurgery. Dr. Samanci completed a clinical fellowship in Gamma Knife Radiosurgery. He has also finished advanced programs in spinal cord and peripheral nerve stimulation. He received several TÜBİTAK postdoctoral research fellowships and the Prof. Dr. Hakan Caner Overseas Education Scholarship from the Turkish Neurosurgical Society.

Dr. Samanci is an active member of several national and international neurosurgical societies. These include the Turkish Neurosurgical Society, the International Parkinson and Movement Disorder Society, and the European Society for Stereotactic and Functional Neurosurgery. He has served on editorial boards and scientific committees. His work reflects significant contributions to academic neurosurgery and research.

Dr. Wuttichai Sutantavibul is an orthopedic surgeon focused on spine care. He specializes in vertebroplasty and kyphoplasty, percutaneous screw fixation, epidural steroid injection, minimally invasive spinal surgery, and endoscopic spine surgery.

Education and fellowships: 2006: Medical degree, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok. 2015: Residency in orthopedic surgery, Ramathibodi Hospital. 2022: Fellowship in spine surgery, Ramathibodi Hospital. 2023: Fellowship in minimally invasive endoscopic spine surgery, Seoul Sangyero Hospital, South Korea. 2023: Minimally invasive and microendoscopic spine surgery training, Wakayama Medical University, Japan.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Experience

2019 – 2019

• University of Insubria, Varese, Italy, 

Insubria University Faculty of Medicine

2015

• MERSİN UNIVERSITY/FACULTY OF MEDICINE, DOCTOR, LECTURER

2013 – 2015

• ANKARA PRIVATE ACIBADEM HOSPITAL

2010 – 2012

• DIYARBAKIR TRAINING AND RESEARCH HOSPITAL,

2002 – 2003

• AYDIN 1ST PRIVATE TRAINING BATTALION
•  

Education

2010

• ANKARA UNIVERSITY FACULTY OF MEDICINE, BRAIN AND SURGERY SPECIALIST

1992

• GAZI UNIVERSITY, FACULTY OF MEDICINE

Dr. Ali Osman Mucuoglu is a neurosurgeon. He completed his neurosurgery residency at Dokuz Eylül University from 2013 to 2019 after graduating from Eskişehir Osmangazi University in 2012 (2005–2012). He worked at Dokuz Eylül University and Muş State Hospital from 2019 to 2021. He has practiced at Atlas University Hospital since 2021.

He has five publications. These include a case report in the International Journal of Surgery Case Reports that has been cited seven times. He also reported on 3D printer‑assisted transsphenoidal hypophysectomy and on emergency minimally invasive intracerebral hemorrhage (ICH) surgery. He delivered an oral presentation at the 33rd Turkish Neurosurgical Society Congress in 2019.

He is a member of the Turkish Neurosurgical Society, the European Association of Neurosurgical Societies, and the Istanbul Chamber of Medicine. His advanced training includes spinal surgery courses in 2016 and 2017, the European Training Course on Head Injury and Functional Neurosurgery in 2017, and Surgical Neuroanatomy in 2017. He also holds an animal experimentation certificate from 2016.

Education & Expertise

1996 to 2000 | Dicle University – Medical Education

Professional Experience

2001 to 2006 | Diyarbakır State Hospital – Neurology Specialist

2006 to 2009 | Düzce Atatürk State Hospital – Neurology Specialist

2009 to 2013 | Düzce University – Associate Professor of Neurology

2013 to 2016 | Düzce University – Associate Professor of Neurology

2017 to 2024 | Pendik Private Century Hospital – Associate Professor of Neurology

2024 to Present | VM Medical Park Pendik Hospital – Associate Professor of Neurology

Courses & Certifications

June, 2012 | Trainer Training Course

February, 2010 | Trainer Training Course

March, 2011 | Sleep Medicine Certification Program Preparation Course

December, 2012 | Sleep Disorders Diagnosis and Treatment Course

DBS Application Training and Course – Dubai

Professional Memberships

Turkish Medical Association

Turkish Neurology Association

Turkish Sleep Medicine Association

Awards & Recognitions

2014 | Düzce University Rectorship – Publication Success Incentive Award

Dr. Apisit Rattanasarn is an orthopaedic surgeon who focuses on foot and ankle disorders. He trained at major academic medical centers in Thailand.

He completed residency in Orthopaedic Surgery and a fellowship in Foot and Ankle Surgery at the Faculty of Medicine, Siriraj Hospital, Mahidol University. He has broad experience in surgical and non-surgical care for degenerative disease, sports injuries, and post‑traumatic conditions.

His practice focuses on accurate diagnosis, joint preservation, pain control, and long-term function. He provides tailored treatment plans. He is a member of the Thailand Orthopaedic Foot & Ankle Society (THOFAS) and the Royal College of Orthopaedic Surgeons of Thailand (RCOST), and is licensed by the Thai Medical Council (TMC).

Lee Sang‑Gu, MD, PhD, is the Honorary Director of Neurosurgery at Naeun Hospital. He treats spinal tumors and disorders. His work includes minimally invasive spine surgery, cervical spine conditions, head trauma, and disability and impairment evaluation.

He previously served as Chief of Neurosurgery at Korea Veterans Hospital. He was also Director and Professor of Neurosurgery at Gachon University Gil Medical Center. He is President of the Korean Spinal Cord Society. He is a former president of KOMISS, the Korean Medical Appraisal Society, and the Korean Peripheral Nerve Society. He has served as Executive Director of the Korean Neurosurgical Society, the Korean Neurotraumatology Society, and the Korean Spinal Neurosurgery Society. He was listed in Marquis Who’s Who in 2010. He is an AOSpine Asia Pacific committee member and a full member of NASS. He earned his MD and PhD from Hanyang University.